Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biocept, Inc.
  6. Summary
    BIOC   US09072V5012

BIOCEPT, INC.

(BIOC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
3.91(c) 3.79(c) 3.78(c) 3.92(c) 4.01(c) Last
683 517 404 384 134 849 342 861 261 836 Volume
+3.17% -3.07% -0.26% +3.70% +2.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 57,8 M - -
Net income 2021 -1,03 M - -
Net Debt 2021 - - -
P/E ratio 2021 -50,1x
Yield 2021 -
Sales 2022 33,1 M - -
Net income 2022 -18,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,58x
Yield 2022 -
Capitalization 59,0 M 59,0 M -
Capi. / Sales 2021 1,02x
Capi. / Sales 2022 1,78x
Nbr of Employees 107
Free-Float 100,0%
More Financials
Company
Biocept, Inc. is an early stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor nucleic acid, including circulating tumor deoxyribonucleic acid (ctDNA) and circulating tumor ribonucleic acid (ctRNA), assays using a standard blood sample or liquid biopsy. Its blood and cerebrospinal fluid (CSF) assays are intended to provide... 
Sector
Medical Equipment, Supplies & Distribution
Calendar
09/22 | 03:45pmPresentation
More about the company
Ratings of Biocept, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOCEPT, INC.
09/07BIOCEPT : to Present at Four Virtual Investor Conferences in September
BU
08/31BIOCEPT : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/19BIOCEPT : Says CNSide Assay Detects Tumor Cells in 100% of Samples From Lung Can..
MT
08/19BIOCEPT : CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarker..
BU
08/19Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomar..
CI
08/16BIOCEPT : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/16BIOCEPT INC : Results of Operations and Financial Condition, Financial Statement..
AQ
08/16BIOCEPT : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
08/16Biocept, Inc. Reports Earnings Results for the Second Quarter Ended June 30, ..
CI
08/16BIOCEPT : Earnings Flash (BIOC) BIOCEPT Posts Q2 Revenue $12M
MT
08/16BIOCEPT : Reports Second Quarter 2021 Financial Results
BU
08/09BIOCEPT : to Report Second Quarter 2021 Financial Results and Host Investor Conf..
BU
08/03BIOCEPT : Names David Karlander as Senior Vice President of Commercial Operation..
BU
08/03Biocept Names David Karlander as Senior Vice President of Commercial Operatio..
CI
07/26BIOCEPT : Corporate Presentation
PU
More news
News in other languages on BIOCEPT, INC.

- No features available -

More news
Chart BIOCEPT, INC.
Duration : Period :
Biocept, Inc. Technical Analysis Chart | BIOC | US09072V5012 | MarketScreener
Technical analysis trends BIOCEPT, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 4,01 $
Average target price 12,00 $
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Michael W. Nall President, Chief Executive Officer & Director
Timothy C. Kennedy CFO, Senior VP-Operations & Secretary
Samuel D. Riccitelli Chairman
Lyle J. Arnold Chief Scientific Officer & Senior Vice President
Michael C. Dugan Chief Medical Officer & Medical Director
Sector and Competitors
1st jan.Capi. (M$)
BIOCEPT, INC.-9.68%59
10X GENOMICS, INC.15.46%18 129
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.32.74%17 939
BIOMÉRIEUX-0.69%15 919
DIASORIN S.P.A.19.11%13 013
NATERA, INC.26.97%11 850